One of the greatest assets of our ongoing Program Project is our network of tumor specimens and the corresponding patient-specific clinical and follow-up database. Every project in the current Program Project has utilized this core, as will all of the projects in this renewal application. This Core will be responsible for receiving all specimens to be used by the various projects, registering these specimens into a computerized data base, maintaining the stored specimens, determining whether the specimens are of sufficient quality for various assays, aliquoting tissue to be sent to other core facilities and laboratories, maintaining a computerized inventory of tissue remaining in the Tumor Banks, retrieving tissue from the Banks upon request by investigators, obtaining continuing clinical follow-up about the patients who provided the tumor specimens, entering data obtained on these tumors by the various cores and projects, and maintaining quality control standards for all data collected. As new laboratory measurements are obtained on our tumor specimens, these results are merged into the existing network. The physical facilities, equipment, and personnel necessary to maintain this Core are already in place. Centralization of tumor banking activities and data collection capabilities into a core facility guarantees optimum efficiency in management of time and resources, and provides an excellent mechanism for quality control.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA030195-21
Application #
6479424
Study Section
Project Start
2001-08-01
Project End
2002-12-31
Budget Start
Budget End
Support Year
21
Fiscal Year
2001
Total Cost
Indirect Cost
Name
Baylor College of Medicine
Department
Type
DUNS #
074615394
City
Houston
State
TX
Country
United States
Zip Code
77030
Park, Jun Hyoung; Vithayathil, Sajna; Kumar, Santosh et al. (2016) Fatty Acid Oxidation-Driven Src Links Mitochondrial Energy Reprogramming and Oncogenic Properties in Triple-Negative Breast Cancer. Cell Rep 14:2154-2165
Pathiraja, Thushangi N; Nayak, Shweta R; Xi, Yuanxin et al. (2014) Epigenetic reprogramming of HOXC10 in endocrine-resistant breast cancer. Sci Transl Med 6:229ra41
Zhang, Yi; Tseng, Chun-Chih; Tsai, Yuan-Li et al. (2013) Cancer cells resistant to therapy promote cell surface relocalization of GRP78 which complexes with PI3K and enhances PI(3,4,5)P3 production. PLoS One 8:e80071
Machado, Heather L; Kittrell, Frances S; Edwards, David et al. (2013) Separation by cell size enriches for mammary stem cell repopulation activity. Stem Cells Transl Med 2:199-203
Zhang, Xiaomei; Claerhout, Sofie; Prat, Aleix et al. (2013) A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models. Cancer Res 73:4885-97
Boone, David N; Lee, Adrian V (2012) Targeting the insulin-like growth factor receptor: developing biomarkers from gene expression profiling. Crit Rev Oncog 17:161-73
Casa, Angelo J; Potter, Adam S; Malik, Simeen et al. (2012) Estrogen and insulin-like growth factor-I (IGF-I) independently down-regulate critical repressors of breast cancer growth. Breast Cancer Res Treat 132:61-73
Creighton, Chad J (2012) Molecular classification and drug response prediction in cancer. Curr Drug Targets 13:1488-94
Pathiraja, Thushangi N; Shetty, Priya B; Jelinek, Jaroslav et al. (2011) Progesterone receptor isoform-specific promoter methylation: association of PRA promoter methylation with worse outcome in breast cancer patients. Clin Cancer Res 17:4177-86
Heckman-Stoddard, B M; Vargo-Gogola, T; Herrick, M P et al. (2011) P190A RhoGAP is required for mammary gland development. Dev Biol 360:1-10

Showing the most recent 10 out of 260 publications